title: Effects of dopamine and glutamate on synaptic plasticity: a computational modeling approach for drug abuse as comorbidity in mood disorders.
abstract: Major depressive disorder (MDD) affects about 16% of the general population and is a leading cause of death in the United States and around the world. Aggravating the situation is the fact that "drug use disorders" are highly comorbid in MDD patients, and VICE VERSA. Drug use and MDD share a common component, the dopamine system, which is critical in many motivation and reward processes, as well as in the regulation of stress responses in MDD. A potentiating mechanism in drug use disorders appears to be synaptic plasticity, which is regulated by dopamine transmission. In this article, we describe a computational model of the synaptic plasticity of GABAergic medium spiny neurons in the nucleus accumbens, which is critical in the reward system. The model accounts for effects of both dopamine and glutamate transmission. Model simulations show that GABAergic medium spiny neurons tend to respond to dopamine stimuli with synaptic potentiation and to glutamate signals with synaptic depression. Concurrent dopamine and glutamate signals cause various types of synaptic plasticity, depending on input scenarios. Interestingly, the model shows that a single 0.5 mg/kg dose of amphetamine can cause synaptic potentiation for over 2 h, a phenomenon that makes synaptic plasticity of medium spiny neurons behave quasi as a bistable system. The model also identifies mechanisms that could potentially be critical to correcting modifications of synaptic plasticity caused by drugs in MDD patients. An example is the feedback loop between protein kinase A, phosphodiesterase, and the second messenger cAMP in the postsynapse. Since reward mechanisms activated by psychostimulants could be crucial in establishing addiction comorbidity in patients with MDD, this model might become an aid for identifying and targeting specific modules within the reward system and lead to a better understanding and potential treatment of comorbid drug use disorders in MDD.
authors.affiliation: Department of Biomedical Engineering, Georgia Institute of Technology and Emory University Medical School, Atlanta, GA 30332-0535, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Qi
authors.forename: S
authors.initials: S
authors.lastname: Kikuchi
authors.forename: F
authors.initials: F
authors.lastname: Tretter
authors.forename: E O
authors.initials: EO
authors.lastname: Voit
mesh_terms: D000661:Amphetamine / Q000494:pharmacology; D015897:Comorbidity; D003198:Computer Simulation; D004298:Dopamine / Q000502:physiology*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D059330:GABAergic Neurons / Q000502:physiology*; D018698:Glutamic Acid / Q000502:physiology*; D006801:Humans; D019964:Mood Disorders / Q000453:epidemiology / Q000503:physiopathology*; D009473:Neuronal Plasticity / Q000187:drug effects* / Q000502:physiology; D018377:Neurotransmitter Agents / Q000502:physiology*; D010766:Phosphorylation / Q000187:drug effects / Q000502:physiology; D015398:Signal Transduction; D019966:Substance-Related Disorders / Q000453:epidemiology / Q000503:physiopathology*
chemical_list: D018765:Dopamine Uptake Inhibitors; D018377:Neurotransmitter Agents; D018698:Glutamic Acid; D000661:Amphetamine; D004298:Dopamine